91 related articles for article (PubMed ID: 16821619)
41. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer.
Chen CH; Lin CM; Kao KC; Chang JW; Tsao TC
Chang Gung Med J; 2007; 30(3):249-55. PubMed ID: 17760276
[TBL] [Abstract][Full Text] [Related]
42. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
[TBL] [Abstract][Full Text] [Related]
43. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.
Di Lorenzo G; Pizza C; Autorino R; De Laurentiis M; Marano O; D'Alessio A; Cancello G; Altieri V; Tortora G; Perdonà S; Bianco AR; De Placido S
Eur Urol; 2004 Dec; 46(6):712-6. PubMed ID: 15548437
[TBL] [Abstract][Full Text] [Related]
44. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.
Dexeus F; Logothetis CJ; Samuels ML; Hossan E; von Eschenbach AC
Cancer Treat Rep; 1985; 69(7-8):885-6. PubMed ID: 4016795
[TBL] [Abstract][Full Text] [Related]
45. Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
Kasimis BS; Moran EM; Miller JB; Forbes KA; Kaneshiro CA; Poblet MT; Williams JL
Cancer Treat Rep; 1983 Oct; 67(10):937-9. PubMed ID: 6688755
[TBL] [Abstract][Full Text] [Related]
46. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study.
Tralongo P; Bollina R; Aiello R; Di Mari A; Moruzzi G; Beretta G; Mauceri G; Conti G
Tumori; 2003; 89(1):26-30. PubMed ID: 12729357
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer.
Bex A; Otto T; Lümmen G; Rübben H
Urol Int; 2002; 69(4):273-7. PubMed ID: 12444282
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
Carles J; Domenech M; Gelabert-Mas A; Nogue M; Tabernero JM; Arcusa A; Guasch I; Miguel A; Ballesteros JJ; Fabregat X
Acta Oncol; 1998; 37(2):187-91. PubMed ID: 9636014
[TBL] [Abstract][Full Text] [Related]
49. A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer.
Fiedler W; Tchen N; Bloch J; Fargeot P; Sorio R; Vermorken JB; Collette L; Lacombe D; Twelves C;
Eur J Cancer; 2006 Jan; 42(2):200-4. PubMed ID: 16337787
[TBL] [Abstract][Full Text] [Related]
50. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.
Sweeney CJ; Monaco FJ; Jung SH; Wasielewski MJ; Picus J; Ansari RH; Dugan WM; Einhorn LH
Ann Oncol; 2002 Mar; 13(3):435-40. PubMed ID: 11996476
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
Oudard S; Caty A; Humblet Y; Beauduin M; Suc E; Piccart M; Rolland F; Fumoleau P; Bugat R; Houyau P; Monnier A; Sun X; Montcuquet P; Breza J; Novak J; Gil T; Chopin D
Ann Oncol; 2001 Jun; 12(6):847-52. PubMed ID: 11484963
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting.
Sewak S; Kosmider S; Ganju V; Woollett A; Yeow EG; Le B; Henry M; Debrincat MA; Bell R
Intern Med J; 2010 Mar; 40(3):201-8. PubMed ID: 19460063
[TBL] [Abstract][Full Text] [Related]
53. Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients.
Berruti A; Mosca A; Bitossi R; Gorzegno G; Guercio S; Poggio M; Tampellini M; Porpiglia F; Ostellino O; Scarpa RM; Dogliotti L
Anticancer Res; 2005; 25(6C):4475-9. PubMed ID: 16334129
[TBL] [Abstract][Full Text] [Related]
54. 5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study.
Huan SD; Aitken SE; Stewart DJ
Ann Oncol; 1994 Sep; 5(7):644-5. PubMed ID: 7993842
[TBL] [Abstract][Full Text] [Related]
55. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer.
Carles Galcerán J; Bastus Piulats R; Martín-Broto J; Maroto Rey P; Nogué Aligué M; Domenech Santasusana M; Arcusa Lanza A; Bellmunt Molins J; Colin C; Girard A
Clin Transl Oncol; 2005 Mar; 7(2):66-73. PubMed ID: 15899211
[TBL] [Abstract][Full Text] [Related]
56. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer.
Robles C; Furst AJ; Sriratana P; Lai S; Chua L; Donnelly E; Solomon J; Sundaram M; Feun L; Savaraj N
Oncol Rep; 2003; 10(4):885-9. PubMed ID: 12792740
[TBL] [Abstract][Full Text] [Related]
57. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).
Berlin JD; Propert KJ; Trump D; Wilding G; Hudes G; Glick J; Burch P; Keller A; Loehrer P
Am J Clin Oncol; 1998 Apr; 21(2):171-6. PubMed ID: 9537206
[TBL] [Abstract][Full Text] [Related]
58. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
Logothetis CJ; von Eschenbach AC; Samuels ML; Trindade A; Johnson DE
Cancer Treat Rep; 1982 Jan; 66(1):57-63. PubMed ID: 7053267
[TBL] [Abstract][Full Text] [Related]
59. [Continuous subcutaneous infusion of peplomycin for advanced prostatic cancer patients].
Satake I; Tari K
Hinyokika Kiyo; 1985 May; 31(5):875-83. PubMed ID: 2413747
[TBL] [Abstract][Full Text] [Related]
60. Oral vinorelbine as first line chemotherapy in unfit elderly patients with hormone-refractory prostate cancer.
Caristi N; Maisano R; Iorfida M; Scimone A; Lupo G; Buda C; Scisca C; Adamo V
J Chemother; 2008 Jun; 20(3):368-73. PubMed ID: 18606594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
